Optilume for recurrent bulbar urethral strictures Optilume is a novel drug-coated balloon that is indicated for the treatment of urethral strictures. The technology combines balloon dilation, to expand or widen the strictured area, and the delivery of an anti-proliferative drug (paclitaxel) intended to reduce the rate of stricture recurrence.
 
Status In progress
Decision Selected
Process MT
ID number 565

Provisional Schedule

Committee meeting: 2 16 September 2022
Resolution 17 October 2022
Expected publication 28 November 2022

Project Team

Project lead federica Ciamponi

Email enquiries

Stakeholders

External assessment group CEDAR
Manufacturers Urotronic
Others Association of British Healthcare Industries (ABHI)
  Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
  Boston Scientific
  Department of Health and Social Care
  Devices for Dignity
  Greater Manchester Health & Social Care Partnership
  Healthcare Improvement Scotland
  HealthTech Alliance
  Johnson & Johnson Medical Ltd
  Medical Technology Group
  Medicines and Healthcare Products Regulatory Agency
  University of Manchester Wounds Research Group
  NHS England
  The British In Vitro Diagnostics Association (BIVDA)
  NHS Digital

Timeline

Key events during the development of the guidance:

Date Update
14 June 2022 - 12 July 2022 Draft guidance: 1
20 May 2022 Committee meeting: 1
26 November 2021 Scope published
04 October 2021 Stakeholder registration opens

For further information on our processes and methods, please see our CHTE processes and methods manual